CCNJL

Across TCGA pan-cancer cohorts, CCNJL Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCNJL data layer compared with 30 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CCNJL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCNJL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, STAD, and PRAD are the cancer types where CCNJL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.168	0.686	<.001	15	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.949	0.829	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CCNJL–HNSC (OS)

Open the HNSC breakdown →